AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Gabapentin is indicated for the management of Postherpetic Neuraligia
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
An accomplished R&D leader and champion of the application of AI to drug discovery
The Institute is catering the health needs of the surrounding population with ever-increasing OPD every year along with special OPDs like mother & Child OPD, and LSD clinic
The workshop was conducted as a part of the NITI–State workshop series
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Arco Lab now holds a 50% stake in Neviton
Subscribe To Our Newsletter & Stay Updated